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Summary 
In comparison with HLA-A and -B, the protein products of the HLA-C locus are poorly charac- 
terized, in part because of their low level of expression at the cell surface. Here, we examine 
how protein-protein interactions during assembly and regulation of the mRNA level affect cell 
surface expression of HLA-C. We find that intrinsic properties of the HLA-C heavy chain pro- 
teins do not correlate with low cell surface expression:  HLA-C heavy chains associate and dis- 
sociate with fl2-microglobulin  (fl2m) at rates comparable to those found for HLA-A and -B, and 
increased competition for fl2m does not alter the surface expression of HLA-C. From studies 
of chimeric genes spliced from the HLA-B7 and -Cw3 genes, we find that chimeric proteins 
containing the B7 peptide-binding groove can have low cell surface expression,  suggesting that 
inefficiency in binding peptides is not the cause of low cell surface expression for HLA-C. The 
surface levels of HLA-A, -B, or -C in cells transfected with cDNA can be similar, implicating 
noncoding regions of HLA-C heavy chain genes in the regulation of surface expression.  We 
find that HLA-C mRNA is expressed at lower levels than HLA-B mRNA and that this differ- 
ence results from faster degradation of the HLA-C message. Experiments examining chimeric 
B7/Cw3 and B7/Cw6 genes suggest that a region determining low expression  of HLA-C is 
to be found between the 3' end of exon 3 and a site in the 3' untranslated region, '~600 bases 
downstream of the translation stop codon. 
H 
LA  class  I  molecules can  be  found on  the  surface 
of most types of human nucleated cells; they function 
in the presentation of endogenously processed  peptide an- 
tigens to CTLs (reviewed in reference 1) and the inhibition 
of NK cells (reviewed in reference 2). The products of the 
HLA-A and -B loci have been well characterized in terms of 
their serology, structure, and function (3-5). In contrast, the 
serology of HLA-C molecules remains crude, which in turn 
has impeded analysis of the structure and function of HLA-C 
(6). Despite these limitations, HLA-C molecules have been 
shown to present peptides to CTLs (7) and to inhibit NK 
cells (8). 
In most human populations, the products of 10-50% of 
the HLA-C alleles are not recognized by the human alloan- 
tisera used in HLA typing and are therefore defined as sero- 
logically "blank" alleles (9). However, biochemical analysis 
(10) and DNA cloning (11, 12) demonstrate that the blank 
alleles are associated with functional genes and that the failure 
of human alloantisera to recognize HLA-C blanks is not caused 
by the absence of a functional HLA-C molecule at the cell 
surface. 
Snary et al. (13) reported in 1977 that HLA-C molecules 
are expressed at the cell surface at levels much lower than 
either HLA-A or -B. Since then, other groups of investigators 
have suggested possible causes for the low surface expression 
of HLA-C molecules. One view is that intrinsic properties 
of HLA-C heavy chain polypeptides are responsible (6). By 
analogy with H-2L  a,  a mouse dass I molecule with rela- 
tively low expression at the cell surface, HLA-C heavy chains 
might associate inefficiently with flz-microglobulin (/3zm)  1 
and peptide in the endoplasmic reticulum (14). Alternatively, 
HLA-C molecules could dissociate more rapidly. In this vein, 
Neefjes and Ploegh (15) have postulated a decreased affinity 
of HLA-C heavy chains for fl2m, owing to HLA-C-specific 
residues  of the or3 domain. 
A second view holds that low HLA-C expression results 
from factors affecting HLA-C mRNA and not from intrinsic 
properties of the HLA-C heavy chain. Shimizu and DeMars 
(16) found that levels of HLA-C mRNA in transfected cells 
1 Abbreviations used in this ~per:  fl2m, /~2-microglobulin; 1D-IEE one- 
dimensional isoelectric gel focusing electrophoresis; HAT, hypoxanthine 
aminopterin  thymidine;  UTR, untranslated  region. 
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Tibensky et al. (12) found similar mlLNA levels for HLA-B 
and -C in EBV-transformed B cell lines. Several different en- 
hancer and promoter elements are present in HLA-A, -B, and 
-C genes, but sequence comparisons revealed no correlation 
between the presence of particular elements and the level of 
cell surface expression (17, 18). However, no direct compar- 
ison of HLA-A, -B, and -C promoters using reporter gene 
constructs has been performed, so the role ofpretranslational 
regulation remains  unclear. 
In summation,  there exists a confusing and contradictory 
literature  pertaining  to  the  low  cell  surface  expression  of 
HLAoC molecules and as yet there is no consensus as to the 
underlying mechanism. The experiments described here were 
undertaken  to help clarify these issues. 
Materials  and Methods 
Nomenclature.  HLA-A, -B, and -C are designated by serolog- 
ical assignment. Where appropriate, the official aUde designations 
are given in parentheses  (19, 20). 
Cell Culture.  Cell lines were cultured in RPMI 1640 (Media- 
tech, Washington, DC) containing 10% BSA (Hyclone, Logan, 
UT), as previously described (21). Jesthom (A2, B27, Cwl), JY 
(A2, B7, Cw7), JAP NF (A2;26, B38;63, Cw7) (22), KT 17 (A2;11, 
B35;62, Cw3;4) (22), GEE018 (A2;29, B7;76, Cw6) (23), GRC187 
(A28;31, B35;62, Cw3) (24), and Olga (A31, B62, Cw11) (22) are 
EBV-transformed  B cell lines. Mutant EBV cell lines we used are 
721.221, which is HLA-A, -B, and -C negative (16); 721.184, which 
expresses only the HLA-Cwl  gene (16); and HmyC1R (CIR), 
which  expresses  Cw4  (Cw*0401)  and  a  small  amount  of B35 
(B'3501) (25). 
Transfection with Genornic DNA.  Genomic clones for HLA-A2 
(A*0201), B7 (B*0702),  B27 (B'2705), Cw3, Cw6, and Cw7 in 
the pHEBo shuttle vector were transfected into the 721.221 cell 
line (16) as previously described (21). 721.221 cells transfected with 
the pHEBo shuttle vector required no selection by flow cytometry, 
as they give a unimodal distribution when analyzed by flow cytom- 
etry after staining with  a class I  HLA-specific mAb.  Unsorted 
hygromycin-resistant ceils were therefore pooled and expanded. At 
least two separate transfections with each chimeric gene were as- 
sayed. Transfectants  were maintained in medium containing 300 
/zg/ml hygromycin B (Boehringer Mannheim Biochemicals, Indi- 
anapolis,  IN) throughout  the culture period. 
In experiments in which the effect of competition for Bzm be- 
tween either HLA-C or -B and -A2 heavy chains  was examined, 
the B7, Cw3, Cw6, or Cw7 gene was transfected into a recipient 
cell, which is itself a transfectant of 721.221 expressing  HLA-A2 
in a stable  fashion.  This recipient cell was made by transfection 
of the HLA-A2 gene (subcloned in the shuttle vector pHtrF32) 
into 721.221 cells and selection  using hypoxanthine aminopterin 
thymidine (HAT) medium (Sigma Chemical Co., St. Louis, MO). 
A pool of HAT-resistant cells were then sorted for HLA-A2 expres- 
sion using a FACStar |  Plus flow cytometer (Becton Dickinson, 
San Jose, CA), and the sorted populations were cultured further. 
The cell line thus obtained has maintained expression of HLA-A2 
during continuous culture in medium lacking HAT for 6 mo. In 
making "double" transfectants using this recipient cell line,  the 
second class I HLA gene was introduced using the pHEBo vector 
and  selection  with  hygromycin B  as  described  in  the previous 
paragraph. 
Transfection with cDNA.  HLA-A, -B, and -C cDNAs were iso- 
luted from EBV-transformed cell lines and characterized as described 
by Domena et al. (26). Clones isolated by these methods contain 
only a portion of the 3' untranslated region (UTR) because the 
3' primer used for PCR amplification of the cDNA binds to a se- 
quence within this region (Fig.  1, insert I0). Sequenced cDNA 
clones were subcloned into the integrating expression vector pBJ1- 
neo (27) (provided by M. Davis, Stanford University, Stanford, CA) 
using SalI and HindlII sites within the cDNA and HindlII and 
XhoI sites within the vector, cDNA constructs were transfected 
using a gene pulser (Bio Pad Laboratories,  Richmond, CA) set 
at a field strength of 625 V/cm at 960/~F.  After transfection, the 
cDNAs were cultured under G418 selection  (1 mg/ml; GIBCO 
BILL, Gaithersburg, MD), which led to discrete  populations of 
class I-positive and class I-negative G418-resistant cells. The G418- 
resistant cells were sorted using a FACStar |  Plus flow cytometer 
to isolate the population of HLA class I-positive cells. Sorting the 
cDNA transfectants was found not to increase the class I expres- 
sion level of the class I-positive population, but merely to elimi- 
nate the population of class I-negative cells. 
Construction of Cw3/B7 and B7/Cw6 Chimeric Genes.  The p158 
plasmid containing the B7 genomic clone was obtained from J. 
Barbosa (Harvard University, Boston, MA), and the pCw3 plasmid 
containing the Cw3 genomic done (28) was from H. Ploegh (Mas- 
sachusetts  Institute of Technology, Cambridge, MA). B7pHEBo 
was generated as described (21). Cw6pHEBo and Cw7pHEBo were 
provided by D. Schendel (Institute for Immunology, Munich, Ger- 
many). DNA containing the EcoRI-XbaI 4.6-kb fragment of Cw3 
was cloned into the pHEBo plasmid  to generate Cw3pHEBo. To 
confirm that the gene downstream of the polyadenylation signal 
of B7 did not contain a control element, we made a construct, 
B7A, in which the region 3' to the BstlI site was deleted in the 
B7 gene (Fig. 1, insert 2). The chimeric genes included Cw3E/B7, 
the Cw3 enhancer fused to the remainder of the B7 gene using 
EcoRI and XbaI (Fig. 1, insert 5); Cw3PL/B7, the B7 enhancer 
fused to the Cw3 promoter through exon 1, fused to the remainder 
of the B7 gene using XbaI and a PCR primer 5'-GGCGGGTCT- 
CAGCCCC; B7E/Cw3, the B7 enhancer element fused to the Cw3 
gene using EcoRl and XbaI (Fig. 1, insert 7); B7E-ex3/Cw3, the 
B7 enhancer through exon 3 fused to the remainder of the Cw3 
gene using EcoRI and KpnI (Fig. 1, insert 8); and B7E-ex3/Cw6, 
the B7 enhancer through exon 3 fused to the remainder of the Cw6 
gene using EcoRI and KpnI (Fig.  1, insert 9). 
All but one of the chimeric genes were generated by ligating 
restriction endonuclease fragments according to standard  proce- 
dures. The exception, Cw3PL/B7 (Fig. 1, insert 6), was made using 
a two-step PCR protocol (29, 30) and contains the Cw3 sequence 
from the XbaI site in the promoter through most of intron 1. All 
PCIL-amplified and cloned DNAs were sequenced to confirm the 
recombinations and identify artifactual mutations. In doing this, 
we discovered differences from the sequence reported by Sodoyer 
et al. (28) for this very same genomic clone. In the promoter, we 
found the CCAAT box (at 73-77 nucleotides upstream of the ini- 
tiation methionine codon) to have the canonical CCAAT sequence, 
not CCGGT as described previously. Furthermore, the coding se- 
quence matched Cw*0302 and not the Cw*0301 sequence deter- 
mined by Sodoyer et al.  (28).  Thus the nucleotide substitutions 
that distinguish C*0301 and C*0302 may all be the result of errors 
in the C*0301 sequence. 
Flow Cytometry.  Surface expression of class I HLA molecules 
was measured by flow cytometry using a FACScan  |  flow cytom- 
eter (Becton Dickinson); data analysis was performed using a VAX 
computer and the Electric Desk program (Herzenberg Laboratory, 
Stanford University).  Approximately 5  x  10  s cells were incubated 
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Figure  1.  Schematic  diagrams of class I gene 
chimeras. In constructs 1-9, the unshaded areas 
represent B7; the vertical striped areas, Cw3; and 
the hatched  areas, Cw6. The translation stop site 
is indicated by Stop, a vertical bar in inserts I and 
I0 and by a corresponding  vertical bar in inserts 
2-9. Insert I: The parent B7 gene. Insert 2:B7 
(3A), B7 truncated in the 3' UTR 160 bp after 
the translation stop site. Insert  3: Cw3, the parent 
Cw3 gene. Insert 4: Cw6, the parent Cw6 gene. 
Insert 5: Cw3E/B7, the enhancer of  Cw3 fused 
with  the remainder of the B7 gene. Insert 6: 
Cw3PL/B7, the promoter and leader sequence 
of  Cw3 fused with the remainder of the B7 gene. 
Insert 7: B7E/Cw3, the enhancer of B7 fused 
with the remainder of the Cw3 gene. Insert 8: 
B7E-ex3/Cw3, the B7 enhancer through exon 
3 fused with the remainder of Cw3. Insert 9: 
B7E-ex3/Cw6, the B7 enhancer through exon 
3 fused with the remainder of  Cw6; the numbers 
below this construct represent kilobases. Insert 
10:  the exon-intron structure of class I HLA 
genes. The left insert shows the relative positions 
of the enhancer, CCAAT box, promoter, and 
leader (L; i.e., exon 1) sequences in relationship 
to the XbaI site. Shaded areas represent exons; 
unshaded areas, introns. Sites for restriction en- 
zymes are R, EcoRI; X, Xba/; K, KPOl; B, BstII. 
The right insert shows the region  believed to con- 
tain sequences  that cause HLA-C mRNA to turn 
over more rapidly than HLA-B  mRNA. The lo- 
cation of the 3' PCR primer used to clone the 
cDNAs is identified in the insert. 
with antibodies  as described (21), except that 2/~g of purified anti- 
body was used in the primary incubation. For analysis of  the cDNA 
transfectants,  2 #g of purified  W6/32 conjugated to fluorescein 
was used. In each experiment, mAb binding to untransfected 721.221 
cells (background binding) was subtracted from mAb binding to 
the transfectant.  Cells transfected with chimeric genes were assayed 
in at least two separate experiments,  using two or more broadly 
reactive  mAbs. 
Isoelectric  Focusing.  Cells  were  metabolically  labeled  with 
[35S]Met/Cys (Amersham Corp., Arlington Heights, IL), immu- 
noprecipitated,  and treated with neuraminidase  as described  (31). 
One-dimensional isoelectric focusing gel electrophoresis  (1D-IEF) 
was performed as described  (31). The gels were exposed  to film 
or to a Phosphorscreen (Molecular Dynamics, Inc., Sunnyvale, CA). 
Class I heavy chain isoforms were quantitated using ImageQuant 
(Molecular Dynamics, Inc.). The three isoforms of Cwl were con- 
sidered together. 
Half-Life  Determination.  The half-lives of HLA-A, -B, and -C 
proteins  were  determined  using  the  formula  k  =  Tz  - 
T1/log~(V2)  -  log2(V  0, where k is the half-life,  T is the time, 
and V is the density of the isoform. The linear part of the curve 
(4-48 h) was used to generate the r  2 value for each data set by 
linear regression:  F values were 0.932, 0.991, and 0.776 for HLA- 
A2,  -B27,  and -Cwl,  respectively. 
RNA  Preparation.  Total cellular RNA was prepared from 2  x 
107 cells using RNAzol (32) according to the manufacturers in- 
structions  (Tel-Test Inc.,  Friendswood,  TX). 
DNA  Labeling and Oligonucleotide  Specificity.  To obtain probes 
for Northern blot analysis, oligonucleotides that bound to the ho- 
mologous sites in the transmembrane domain of  either the HLA-B 
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or -C sequence and have similar G/C content were designed.  100 
pmol of either the "HLA-B-specific" oligonucleotide (5'-AGC- 
TCCGATGACCACAAC'I~C) or the "HLA-C-specific" oligo- 
nucleotide (5'-AGCTCCTAGGACAGCI'CAGAC),  where bold- 
face letters indicate the nucleotide differences, was end labeled with 
['y:2P]ATP (Amersham  Corp.)  using  T4  polynucleotide kinase 
(Boehringer Mannheim Biochemicals).  Labeled oligonucleotides 
were separated on a Sephedex G50 column (Pharmacia  LKB Bio- 
technology Inc., Alameda, CA). 1 ml of each sample was assayed 
using a scintillation  counter (LS5000CE;  Beckman Instruments, 
Fullerton, CA), and an equivalent  amount of radioactivity for ei- 
ther the HLA-B-specific or -C-specific oligonucleotide was added 
to each hybridization mixture. 
To demonstrate the specificity of the oligonucleotides,  samples 
of total cellular RNA isolated from 721.221 transfectants expressing 
the A2, B7, B27, Cw3, Cw6, or Cw7 gene and from the mutant 
cell line 721.184, which expresses a single copy of the Cwl gene, 
were analyzed on a Northern blot. The oligonucleotide designed 
to be HLA-B-specific bound RNA from the B7 and B27 transfec- 
tants,  but not RNA from any other transfectant  or mutant cell 
lines. The oligonucleotide designed  to be HLA-C-specific bound 
P,  NA from the Cw3, Cw6, and Cw7 transfectants  and 721.184, 
but not from the other cell lines. This assay demonstrated that the 
two oligonucleotides  distinguish HLA-B and -C mRNA. 
To demonstrate that the radiolabeled oligonucleotides had equiva- 
lent specific activity, we analyzed the binding of the HLA-B- and 
-C-specific oligonucleotides  to  150-300  fmol  of B7  and  Cw3 
plasmid DNA and quantitated  the binding using a Phosphorlmager 
(Molecular  Dynamics, Inc.).  In three  separate  experiments,  the 
amount of HLA-B-specific oligonucleotide bound to B7 DNA was comparable to the amount of HLA-C-specific  oligonucleotide  bound 
to Cw3 DNA. 
Clone HHCSA65 (American Type Culture Collection, Rock- 
ville, MD), an 18S ribosomal cDNA, was used as a positive control 
on Northern  blots (33). This probe was labeled with [3~P]CTP 
using random oligonucleotide  primers (Boehringer Mannheim Bio- 
chemicals). Labeled  cDNA was separated from other reaction prod- 
ucts on a Sephedex GS0 column. 
Northern Blot Analysis.  20 #g of total RNA was loaded onto 
each lane of a formaldehyde  gel (34). Each assay was performed 
in duplicate. After electrophoresis, the KNA was transferred onto 
a Nytran membrane (Schleicher  & Schuell, Inc., Keene,  NH) using 
10x  SSC downward transfer (35). After wetting and prehybridi- 
zation, 2-4  x  10  s cpm of labeled HLA-B-- or HLA-C-specific  oli- 
gonucleotide  was added to the hybridization  mixture and incubated 
overnight at 55~  After hybridization,  the membranes  were washed 
twice at room temperature in 1￿  SSC, 0.1% SDS, followed by 
a 1-h wash at 55~  in lx  SSC, 0.1% SDS. The binding of each 
oligonucleotide  was analyzed on a Phosphorlmager. After quanti- 
tation of mRNA, the membranes were stripped by washing them 
at 90~  in 0.1% SDS for 16 h and then reanalyzed using 1-4  x 
107 cpm of the 18S ribosomal probe and the same conditions for 
hybridization and washing. 
Quantitation ofmRNA Levels.  After incubation on a Phosphor- 
screen, the amount of KNA in each lane was calculated, and the 
background radioactivity was subtracted. The amount of mRNA 
in each lane was normalized to the amount of 18S ribosomal KNA 
in the same lane. Data are presented as a percentage of ribosomal 
KNA. 
Actinomycin D Treatment  and HalfiLife Determination. Actinomycin 
D was added at 4-6 rag/5-9  x  10  s cells//A (36). Aliquots of 107 
cells were collected  from actinomycin  D-treated and untreated con- 
trol samples at times from 0 to 8 h after initiation of treatment. 
Generally, the levels of KNA became undetectable after 3-5 h of 
treatment, depending upon the experiment. 10-20 mg of KNA 
was loaded on each lane, and each sample was assayed  in duplicate. 
After quantitation using the HLA-B- or -C-specific oligonucleo- 
tide, the membranes  were stripped and reprobed with the 18S ribo- 
some probe. 18S ribosomal KNA was selected as the control be- 
cause it is unaffected by actinomycin D  treatment  (37). After 
normalizing the amount of HLA-B or -C message to the amount 
of 18S ribosomal KNA in each lane, the half-life  of each message 
was calculated according to the formula k  --  T1  -  T2/log2(Vz) 
-  log2(Vl), where k is the half-life, T is the time, and V is the 
normalized value of the message, r  2 values were calculated to be 
0.999 for the HLA-B message and 0.976 for the HLA-C message. 
Results 
HLA-C Molecules Have Lower Cell Surface Expression than 
HLA-A or-B,  Using quantitative serology, Snary et al. (13) 
found the amount of HLA-C protein expressed by lympho- 
cytes to be ,,o10% that of either HLA-A or -B. The validity 
of this comparison has been uncertain because  different al- 
loantisera were used to quantitate HLA-A, -B, and -C.  In 
reinvestigating the question of HLAoC expression, we elimi- 
nated this variable by using mAbs that react with all HLA-A, 
-B, and -C products and cell lines expressing single HLA-A, 
-B, or -C alleles. Among the cells examined were transfec- 
tants of cell line 721.221, which is HLA-A, -B, and -C nega- 
tive and expresses single HLA-A, -B, or -C alleles; C1K, a 
mutant cell line that expresses Cw*0401 and a small amount 
of B'3503;  and 721.184, which expresses Cwl as the only 
HLA-A, -B, and -C product. 
Cell surface expression was compared by an indirect binding 
assay using flow cytometry. Results obtained with the mono- 
morphic W6/32 antibody are shown in Table 1. Comparable 
levels of binding were seen for 721.184, C1K, and 721.221 
cells transfected with Cw3, Cw6, or Cw7 genomic clones 
in the pHEBo expression vector. The levels of  HLA-C in these 
cells were 15-35% of those seen for genomic pHEBo trans- 
fectants expressing  single HLA-A or -B alleles. In these ex- 
periments,  transfected cells were selected  for resistance  to 
hygromycin B and not for levels of class I HLA expression. 
Thus the relative levels of HLA-A, -B, or -C expression were 
not biased selectively by the transfection procedure. The levels 
of class I expression  observed  for the genomic HLA-A and 
-B transfectants of 721.221 were comparable to those found 
for "normal" EBV-transformed  B cell lines, consistent with 
the results of Sugden et al. (38) and indicating that expres- 
sion of HLA-A, -B, and -C from genomic DNA constructs 
in the transfected mutant cells approximates that of EBV- 
transformed B lymphocytes. (Similar  results were obtained 
from experiments using five mAbs against monomorphic epi- 
topes different from those recognized by W6/32.) Our results, 
consistent with those of Snary et al. (13), show that cell sur- 
face expression  of HLA-C is considerably lower than either 
HLA-A or -B expression. 
HLA-A, -B, and-C Molecules Have Similar Kinetics of  Associ- 
ation and Dissociation with l~2m.  A possible cause of low sur- 
face expression is a slow rate of association of HLA-C heavy 
chains  with/32m.  We examined the rate of association  of 
HLA-A, -B, and -C heavy chains with ~2m in pulse-chase 
experiments. B cell lines were radiolabeled  metabolically for 
30 or 60 s, followed by addition of  excess nonradioactive amino 
acids. HLA-A, -B, and -C heavy chains associating with 32m 
were then isolated using mAb W6/32, which is specific for 
the complex, whereas free HLA-B and -C heavy chains were 
isolated using HC10, an mAb specific for free heavy chains. 
The immunoprecipitates were analyzed by 1D-IEF,  which 
permits direct comparison of the heavy chain allotypes (Fig. 2). 
B7,  B27,  and Cw7 associated  with 32m  during the 30-s 
labeling,  showing that at least one HLA-C molecule can as- 
sociate rapidly with 32m. 
During the 30-s period of labeling, 32m associated with 
the A2 heavy chains in JY cells, but not those in Jesthom 
cells. Even after a 60-s labeling period, neither the A2 nor 
the Cwl heavy chains in Jesthom cells associated with 32m. 
In contrast, the B27 heavy chain in Jesthom cells associated 
with/~2m within 30 s. These data show how the rate of as- 
sociation for the same class I heavy chain can vary among 
B cell lines. 
Experiments in which 5-rain labelings were followed by 
chase periods of various length demonstrated association  of 
A2,  A28,  B53,  Cw4,  and  Cw6  heavy chains with ~2m 
within 5 min, whereas Cwl required 15 min (data not shown). 
Thus, we find that HLA-C heavy chains associate with ~2m 
in a time frame similar  to that observed  for HLA-A and -B 
heavy chains.  From these experiments, we also determined 
that a cohort of Cw4, Cw6, and Cw7 heavy chains corn- 
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Experiment number 
Cell line  1  2  3  4  5 
C1R*  18S(24)"  ND I  ND  ND  20(22) 
721.184"  24(32)  ND  ND  ND(15)  19(21) 
Cw3*  22(30)  24(48)  21(22)  21(15)  27(30) 
Cw6*  25(34)  17(34)  16(17)  34(24)  ND 
Cw7*  21(28)  ND  ND  21(15)  15(17) 
B7*  74(100)  50(100)  94(100)  142(100)  90(100) 
B27'  69(93)  ND  ND  ND  80(89) 
B7A*  ND  ND  ND  145(102)  100(111) 
Cw3E/B7*  70(95)  53(106)  90(96)  ND  ND 
Cw3PL/BY*  68(92)  60(1.2)  65(69)  139(98)  97(108) 
B7E/Cw3*  19(26)  15(30)  15(16)  12(8)  37(4) 
B7E-ex3/Cw3*  21(28)  28(56)  30(32)  45(32)  NDA 
B7E-ex3/Cw6*  ND  ND  19(20)  49(34)  ND 
* Mutant EBV-transformed B lymphocyte cell lines. CIR expresses Cw*0401 and a very low level of B'3503;  721.184 expresses Cwl as the only 
class I molecule. 
t Transfectants of the cell line 721.221, which is negative for HLA-A, -B, and -C. Each cell line is named for the transfected genomic DNA.  B7D 
is the truncated B7 molecule shown in Fig. 1, line  2, Cw3E/B7 is the chimera shown in line  5, Cw3PL/B7 is the chimera shown in line 6, B7E/Cw3 
is the chimera shown in line 7, B7E-ex3/Cw3 is the chimera shown in line 8, and B7E-ex3/Cw6 is the chimera shown in line 9. 
S In each experiment, binding of mAb W6/32 to untransfected 721.221 cells was subtracted from W6/32 binding to the tested cell. The values 
of W6/32 binding to untransfected 721.221 cells were 5, 7, 7, 6, and 6 fluorescence  units in experiments 1, 2, 3, 4, and 5, respectively. Data were 
collected on a four-decalogue scale. 
IM In parentheses, the W6/32 binding is shown as a percentage of the binding obtained with  the HLA-B7 transfectant in the same experiment. 
I ND,  not done. 
plete association with ~2m within 1 h  (data not shown).  In 
conclusion,  this  analysis  indicates  that  slow or incomplete 
association with B~m is unlikely to be a general cause of the 
low  surface  expression  of HLA-C  molecules. 
Another potential cause of low expression is that HLA-C 
molecules have a shorter half-life than HLA-A and -B, a mech- 
anism that accounts for the reduced expression of H-2D  a rel- 
ative to other mouse class I molecules (39). To compare the 
dissociation kinetics, we performed additional pulse-chase ex- 
periments. Jesthom  cells were labeled for 15 min and  then 
chased with  nonradioactive amino  acids over a  5-d period. 
HLA-A, -B, and -C heavy chains were immunoprecipitated 
with W6/32 and analyzed on a 1D-IEF gel. By quantitating 
the  amount  of  heavy  chains  remaining  in  the  W6/32- 
recognizable form during the chase periods, we estimated the 
half-life for each allotype.  The half-lives for A2,  B27,  and 
Cwl were 18, 30, and 15 h, respectively (Fig. 3); these results 
show that  Cwl  does not dissociate significantly faster than 
A2.  Thus, a short half-life is probably not the cause of low 
surface expression for HLA-C molecules. Overall, these data 
do not support the view that HLA-C heavy chains have, as 
a group, slow association and/or rapid dissociation kinetics 
compared with  their  HLA-A  and  -B counterparts. 
Competition for ~2m Does Not Alter the Surface Expression 
of  HLA-C Molecules.  Neei~es and Ploegh (15) have suggested 
that low surface expression of HLA-C molecules derives from 
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poor affinity of the HLA-C heavy chains for 32m. If HLA-C 
heavy chains  bind  poorly to 32m,  then  transfectants  con- 
taining a single HLA-C gene should have higher surface ex- 
pression than transfectants containing both an HLA-A and 
Figure  2.  ID-IEF  gel. JY and Jesthom cells were biosynthetically la- 
beled with [3SSlmethionine  for 30 or 60 s. The cells were lysed, and the 
class I molecules  were  immunoprecipitated  with either mAb W6/32, which 
recognizes HLA-A, -B, and -C class I heavy chains associated  with/3~m, 
or mAb HC10,  which recognizes free HLA-B and -C heavy  chains. 1000000 
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Figure 3.  A log-log plot showing the decay of A2, B27, and Cwl molecules. Jesthom cells were pulse labeled with [3sS]methionine  and then chased 
with nonradioactive methionine for 1-5 d. At each time point, aliquots of cells were lysed, and the class I HLA molecules were immunoprecipitated 
with mAb W6/32. The immunopredpitates  were treated with neuraminidase to remove sialic acid residues and were analyzed by 1D-IEF. After exposure 
to a Phosphorscreen, the samples were analyzed and quantitated  on a Phosphorlmager. 
HLA-C gene. We performed experiments to examine the ca- 
pacity of HLA-C heavy chains to bind B2m in the presence 
and absence of competing HLA-A2 heavy chains. Cell sur- 
face expression of the HLA-C and -A2 molecules was mea- 
|  I  Ii 
sured using indirect antibody binding  and flow cytometry. 
The surface expression for HLA-C molecules was detected 
using mAb 4E, which recognizes HLA-B and -C molecules 
but not HLA-A2 molecules  (40); the surface expression of 
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Figure 4.  Comparison of the surface ex- 
pression of A2, B7, Cw3, Cw6, and Cw7 
molecules on singly and doubly transfected 
cells as assayed by flow cytometry. The ex- 
pressed class I molecttles  are as indicated  under 
each cell line. The surface expression of class 
I molecules was assessed using a four deca- 
logue scale. The y axis shows the change in 
antibody binding. The change in fluorescence 
was calculated  by subtracting the fluorescence 
obtained by staining the untransf~cted  721.221 
cell line with either the MA2.1 or the 4E an- 
tibody from  the fluorescence obtained  by 
staining transfectants  with the same antibody. 
Unshaded bars show MA2.1 binding; black 
bars  show  4E  binding. Values of MA2.1 
binding to the B7, Cw3, Cw6, and Cw7 
transfectants and of 4E binding to the A2 
transfectant  were  the same as binding to 
721.221 cells. A2 was detected using  mAb MA2.1,  which is  specific  for 
A2 and B17 (41). We found that transfected cells expressing 
a single HLA-C gene have the same level of surface expres- 
sion as those expressing A2 in addition to the HLA-C gene 
(Fig.  4).  Thus,  competition for/~2m by A2 has  no observ- 
able effect on the cell surface expression of HLA-C. Transfec- 
tants  expressing  A2 alone  or A2 in  conjunction  with  B7, 
Cw3, Cw6, or Cw7 have similar expression levels, showing 
that  competition for B2m by these other heavy chains does 
not affect the surface expression of A2 (Fig.  4). This is true 
for both the mean fluorescence values (Fig.  4) and the shape 
of the histogram (data not shown). This analysis  shows that 
competition  for/]2m  does not  limit  surface expression  of 
HLA-C molecules,  and low surface expression is  therefore 
unlikely  to  stem from low affinity for Bzm. 
HLA-A, -13, and -C cDNAs Can Direct Comparable Expres- 
sion Levels in Transfected Cells.  Additional evidence that the 
structure of HLA-C heavy chains does not cause low cell sur- 
face expression was obtained by analysis  of cDNA transfec- 
tants (Fig.  5). cDNAs for various HLA-A, -B, and -C alleles 
were subcloned into pBJl-neo, an integrating expression vector, 
and transfected into the HLA class  I-negative  721.221  cell 
line.  The pBJl-neo vector has  a hybrid viral promoter that 
drives expression of the inserted cDNA (42).  Additionally, 
the HLA class I cDNAs used in these constructs do not con- 
tain the entire 3' UTR. Thus, unlike transfection of genomic 
constructs,  this  system is not  subject to locus-specific pro- 
moter  or enhancer  effects on  gene expression. 
Constructs encoding HLA-C molecules were transfected 
multiple times to generate independent transfected cell lines 
expressing the same alleles. Class I expression levels of these 
transfectants varied (Fig.  5). Expression level differences were 
not correlated with particular  alleles,  suggesting they were 
more likely caused by differences in the  site of integration 
or copy number of the transfected genes than to properties 
of the expressed protein product. Significantly,  in this system 
many of the HLA-C transfectants  showed expression levels 
equivalent to or exceeding those of HLA-A and -B transfec- 
tants. This shows that HLA-A, -B, and -C molecules can be 
expressed at similar levels. Furthermore,  some of the HLA-C 
transfectants  had high class I  expression comparable to the 
total class I expression of an EBV-transformed B cell line, in- 
dicating that HLA-C proteins have the capacity to be expressed 
at  high  levels. 
Low Cell Surface Expression Is Determined by a Region of the 
HLA-C Gene 3' to Exon 3.  To identify regions of the HLA-C 
gene responsible for low surface expression, we made a series 
of chimeras between B7 and Cw3 genomic DNA clones (Fig. 
1).  These chimeras  were subcloned into  the  shuttle vector 
pHEBo and transfected into the 721.221  cell line.  Cell sur- 
face expression of the products of the transfected genes was 
assessed by indirect antibody binding using flow cyfometry. 
From analysis  of the five chimeric genes, we obtained evi- 
dence suggesting that  surface expression may be controlled 
by a region  beginning  at  the 3'  end of exon 3  and ending 
in the 3' UTR ~600 bases downstream from the translation 
stop site.  The most informative comparisons are the trans- 
fectants containing the B7 enhancer fused to the remainder 
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Figure 5.  Comparison  of the HLA-A, -B, and -C cell surface  expres- 
sion levels  of cDNA transfectants of the 721.221 cell  line. Class I expres- 
sion was measured  by flow cytometry  using the monomorphic anti-HLA 
mAb W6/32 directly conjugated to fluorescein. The x axis shows the 
median fluoresence intensity of arbitrary units, after subtraction of the 
background staining of the untransfected 721.221 cell line (4.9 fluores- 
cence  units). The fluorescence  intensity  of an EBV-transformed  B cell  stained 
with fluorescein-conjugated  W6/32 is represented  by the dotted  line across 
the graph (505  fluoicscence  units). The World  Health Organization nomen- 
clature designation  (19)  of the transfected  HLA alleles  is shown  on the y axis. 
of the Cw3 gene and the enhancer through to exon 3 of B7 
fused to the 3' part of the Cw3 gene (Table 1). Transfectants 
containing  either  of these chimeras  had  surface expression 
levels similar to those of the transfectant  containing the pa- 
rental  Cw3  gene. 
To investigate the role of a region downstream from exon 
3,  we generated an additional  chimeric  gene by fusing the 
enhancer  through  exon 3 of B7 to exons 4 through  the 3' 
UTR of Cw6. The transfectant  expressing  this chimera (B7E- 
ex3/Cw6) has cell surface levels of class I molecules similar 
to the transfectant  expressing the parental  Cw6 gene,  fur- 
ther  indicating  that  the region controlling  low surface ex- 
pression  is  downstream  from  exon  3. 
Exchanging the enhancer and promoter of the B7 and Cw3 
genes has little effect on cell surface expression, showing that 
regulatory sequences in the 5' region, including the promoter 
of HLA-C, are not responsible for the low expression levels. 
These results concur with the conclusions of Tibensky et al. 
(18) and Steinle et al. (17). Transfectants  expressing the "wild- 
type" B7 gene and a B7 construct truncated in the 3' UTR, 
360 bases after the translation  stop site,  have similar expres- a  70.00% 
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Figure  6.  Comparison of HLA-B and -C 
message levels by Northern blot analysis of 
total cellular  RNA.  (a) Different mRNA 
preparations of the homozygous cells lines 
Jesthom  and JY.  (b) mRNA  preparations 
from  cell  lines JAP  NF,  KT17,  GEE018, 
GRC187 and Olga, which are heterozygous 
for HLA-A, -B, and -C. After exposure  to 
a Phosphorscreen, the amount of either HLA- 
B- or -C-specific oligonucleotide was deter- 
mined and normalized to the amount of 18S 
ribosomal RNA in each sample. White bars 
represent binding by the HLA-B-specific oli- 
gonucleotide; black bars represent binding by 
the HLA-C-specific oligonucleotide. 
sion levels, showing that the sequence of the 3' UTR down- 
stream from the truncation in B7 has no effect on cell surface 
expression.  In aggregate,  these experiments  show the low 
surface expression of HLA-C proteins to be determined by 
a region delimited by the 3' end of exon 3 to the 3' UTR, 
"~600 bases after the translation  stop codon. 
HLA-C  Message Levels Are Lower than HLA-B Message 
Levels.  Shimizu  and DeMars  (16)  noted that  the mRNA 
levels for transfected HLA-C genes were lower than  those 
for either the HLA-A or -B gene. Reduction in mRNA might 
also explain why "normal" B cell lines express less HLA-C 
than either -A or -B. To address this question, we compared 
the amount of HLA-B and -C message by Northern blotting 
using radiolabeled HLA-B- or -C-specific oligonucleotides. 
Analysis of independent preparations of total cellular RNA 
from the Jesthom and JY cell lines  showed the amount of 
HLA-B message to be between 2 and >10 times greater than 
the amounts of HLA-C (Fig. 6 a). Testing additional cell lines 
gave similar results (Fig.  6 b). Thus, low surface expression 
of HLA-C is correlated with  low mRNA levels. 
HLA-C Message Has a Shorter Half-Life  than HLA-B Mes- 
sage.  Low surface  expression of HLA-C molecules corre- 
sponds to the presence of HLA-C sequences downstream from 
exon 3.  Assuming  the low surface  expression results from 
reduced mRNA levels, a sequence downstream  from exon 
3 is its most likely cause.  Regulation of expression by the 
3' part of a gene is usually caused by an element that destabi- 
lizes  the message (37).  To compare the stability of HLA-B 
and -C messages, we treated the cell line Jesthom with ac- 
tinomycin D, an inhibitor of transcription  initiation,  and quan- 
titated HLA-B and -C mRNA after different time periods 
of treatment by Northern blotting using locus-specific oli- 
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Figure  7.  A  semi-log plot showing the 
decay of HLA-B and -C mRNA. Jesthom 
cells were treated  with actinomycin D, and 
total cellular RNA was collected at various 
time points. These samples were analyzed by 
Northern  blot  using  either  HLA-B- or  - 
C-specific oligonucleotides.  After exposure 
to a Phosphorscreen,  the amount of either 
HLA-B- or -C-specific oligonucleotide  was 
determined  and normalized  to the amount 
of 18S ribosomal RNA in each sample. We 
have arbitrarily designated the highest value 
(the HLA-B message at 1 h of treatment)  as 
1.00. 
gonudeotides. The half-life for B27 mRNA was found to 
be  ~03  h,  whereas that  for Cwl  was  ~0.75  h  (Fig.  7). 
Thus, HLA-C message is found to turn over more quickly than 
HLA-B message, resulting in a lower steady-state level of 
HLA-C mRNA. In turn, this is expected to reduce the rates 
of translation,  synthesis of HLA-C heavy chains, assembly 
of HLA-C molecules, and ultimately their steady-state levels 
at the cell surface. 
Discussion 
We find levels of HLA-C molecules at the cell surface to 
be 15-35% those of HLA-A and -B, similar to the differences 
reported by Snary et al. (13). In B cell lines,  the reduced ex- 
pression of HLA-C protein correlates with a lower level of 
HLA mRNA. Our results are consistent with previous com- 
parisons of HLA-A, -B,  and -C mRNA levels in a variety 
of cell types (16,  43-46),  but they contrast with those of 
Tibensky et al.  (12),  who reported similar levels in EBV- 
transformed B cell lines. A possible explanation for the differ- 
ence is that the oligonudeotide probe used by Tibensky et 
al.  to  detect HLA-C  cross-hybridized with  HLA-B.  The 
specificities of our antisense oligonucleotide probes were de- 
termined using I~NA, whereas Tibensky et al. used plasmid 
DNA. Oligonucleotides bind more tightly to RNA than to 
DNA, so that the conditions established by Tibenksy et al. 
to be specific for DNA may not have been as specific for RNA. 
In preliminary assessment of oligonucleotides designed to be 
specific for HLA-B or -C, we found several putative HLA-C- 
specific oligonucleotides that bound nonspecifically to RNA 
prepared from HLA-B transfectants. Indeed, the oligonucleo- 
tides we eventually used were the fourth pair assessed for ap- 
propriate specificity. 
In contrast to our findings, Neefjes and Ploegh (15) have 
suggested that  HLA-C  heavy chains associate  slowly and 
inefficiently with 3zm. In reaching their conclusions,  Neef~es 
and Ploegh (15) assumed that a polyclonal rabbit antisera had 
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a similar af~nity for free HLA-A, -B, and -C heavy chains 
as mAb W6/32 has for 32m-associated heavy chains, which 
may not have been the case. We find that anti-heavy chain 
antisera and mAb vary in their abilities  to recognize heavy 
chain allotypes. Evidence for this phenomenon can also be 
seen in the 1D-IEF gels presented by Neefjes and Ploegh (15), 
in which more HLA-B27 heavy chain is immunoprecipitated 
by the anti-heavy chain antisera than by W6/32,  whereas 
the reverse is true for HLA-All heavy chains. Thus, the larger 
amount of HLA-C flee heavy chain detected by their rabbit 
antisera may have been a consequence more of its higher affinity 
for HLA-C than of the level of HLA-C translation. 
Our study points to low levels of mKNA being the cause 
of low HLA-C expression at the cell surface. In our current 
working hypothesis, it is the rate of HLA-C heavy chain bio- 
synthesis that limits cell surface expression and not intrinsic 
defidencies in either the HLA-C heavy chain or peptide supply, 
as suggested previously (6, 15). Furthermore, the lower levels 
of HLA-C mRNA are due to a higher rate of degradation 
caused by sequences within a region in the 3'  part of the 
HLA-C gene that begins 3' to the end of exon 3 and ends 
in the 3' UTK,  ~600 bases downstream of the translation 
stop site. The fact that cells transfected with cDNA can ex- 
press HLA-C at high levels indicates that the elements con- 
trolling HLA-C expression levels are not a function of the 
exons and is consistent with their location in introns or the 
3' UTR. Given that turnover of the mature spliced mRNA 
is affected,  the most likely location for the regulatory ele- 
ment is in the 3' UTK, downstream of the binding site for 
the oligonucleotide primers used to clone the cDNA (Fig. 
1, insert 10). In HLA-B and -C sequences,  the first polyade- 
nylation signal occurs 90 or 170 bases,  respectively,  down- 
stream from the end of the cDNA  transcript.  Thus,  the 
HLA-C message rearranged from genomic transcripts could 
be 80 bases longer than the HLA-B message and could, in 
that additional segment, contain distinctive regulatory ele- 
ments. Little is known about the mechanisms of mRNA degra- 
dation. Caput et al.  (47)  have shown that a repeating oc- 
tomer, UUAUUUAU, in the 3' UTR destabilizes cytokine 
mRNA. The presence of A/U-rich regions destabilizes  the 
binding of the poly(A)-binding protein (48). Moreover, c-myc 
and c-fos share an A/U-rich region with cytokine genes, al- 
though both protooncogenes have additional destabilizing 
elements within the translated protein (49, 50). HLA-C genes 
do not have A/U-rich sequences in their 3' UTRs and may 
not be regulated by mechanisms similar to those found for 
cytokines and protooncogenes. Clearly, future experiments 
should be directed at a more precise definition of the regula- 
tory elements destabilizing HLA-C  mRNA. 
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